膜联蛋白A2过表达在肝细胞癌发生发展中的作用

张海健; 姚登福; 秦呈林

膜联蛋白A2过表达在肝细胞癌发生发展中的作用

南通大学附属医院临床医学研究中心

基金项目:

江苏省自然科学基金资助(BK2008187)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 4477
- HTML全文浏览量: 20
- PDF下载量: 1343
- 被引次数: 0
出版历程
- 出版日期: 2011-07-20

The role of annexin A2 overexpression in the development and progression of hepatocellular carcinoma

Research funding:

摘要

摘要: 膜联蛋白A2与S100A10组装成异四聚体转位细胞膜从而激活相关信号通路或者Ser25磷酸化以后进入细胞核参与DNA合成和细胞增殖,可调节血管形成、与肝细胞癌(HCC)形成与预后相关。本文综述了膜联蛋白A2的分子构成、功能及对HCC诊断和预后价值的研究进展。
- 癌,肝细胞 /
- 膜联蛋白A2
Abstract: Annexin A2 can translocate to the outer membrane surface and activate correlative signaling pathway through assembling heterotetramer with S100A10, and can enter nucleus and participate in DNA synthesis and cell proliferation after its Ser25 is phosphorylated.It regulates angiogenesis, involves formation of hepatocellular carcinoma (HCC) , and affects the prognosis of HCC.This review summarizes recent studies of its molecular constitution, function and the values of diagnosis and prognosis for HCC.
- carcinoma /
- hepatocellular

HTML全文

参考文献(28)

[1]Hoshida Y, Toffanin S, Lachenmayer A, et al.Molecularclassification and novel targets in hepatocellular carcinoma:recentadvancements[J].Semin Liver Dis, 2010, 30 (1) :35-51.

[2]Stefaniuk P, Cianciara J, Wiercinska-Drapalo A.Present and futurepossibilities for early diagnosis of hepatocellular carcinoma[J].World J Gastroenterol, 2010, 16 (4) :418-424.

[3]Sun Q, Zhang Y, Liu F, et al.Identification of candidate biomarkersfor hepatocellular carcinoma through pre-cancerous expressionanalysis in an HBx transgenic mouse[J].Cancer Biol Ther, 2007, 6 (10) :1532-1538.

[4]Gerke V, Moss SE.Annexins:from structure to function[J].PhysiolRev, 2002, 82 (2) :331-371.

[5]Rescher U, Gerke V.S100A10/p11:family, friends and functions[J].Pflugers Arch, 2008, 455 (4) :575-582.

[6]Mohammad HS, Kurokohchi K, Yoneyama H, et al.Annexin A2expression and phosphorylation are up-regulated in hepatocellularcarcinoma[J].Int J Oncol, 2008, 33 (6) :1157-1163.

[7]He KL, Deora AB, Xiong H, et al.Endothelial cell annexin A2regulates polyubiquitination and degradation of its binding partnerS100A10/p11[J].J Biol Chem, 2008, 283 (28) :19192-19200.

[8]Dassah M, Deora AB, He K, et al.The endothelial cell annexin A2system and vascular fibrinolysis[J].Gen Physiol Biophys, 2009, 28:F20-28.

[9]Li Q, Ke F, Zhang W, et al.A role for the annexin A2 amino-terminal peptide in the plasmin-induced activation of humanperipheral monocytes[J].Mol Immunol, 2010, 47 (14) :2405-2410.

[10]Luo W, Yan G, Li L, et al.Epstein-Barr virus latent membraneprotein 1 mediates serine 25 phosphorylation and nuclear entryof annexin A2 via PI-PLC-PKCalpha/PKCbeta pathway[J].MolCarcinog, 2008, 47 (12) :934-946.

[11]Gao PJ, Shi Y, Gao YH, et al.The receptor for beta (2) GP I onmembrane of hepatocellular carcinoma cell line SMMC-7721 isannexin II[J].World J Gastroenterol, 2007, 13 (24) :3364-3368.

[12]Huang Y, Jin Y, Yan CH, et al.Involvement of Annexin A2 in p53induced apoptosis in lung cancer[J].Mol Cell Biochem, 2008, 309 (1-2) :117-123.

[13]Kapoor M, Zhou Q, Otero F, et al.Evidence for annexin II-S100A10 complex and plasmin in mobilization of cytokine activityof human TrpRS[J].J Biol Chem, 2008, 283 (4) :2070-2077.

[14]Kesavan K, Ratliff J, Johnson EW, et al.Annexin A2 is a moleculartarget for TM601, a peptide with tumor-targeting and anti-angiogenic effects[J].J Biol Chem, 2010, 285 (7) :4366-4374.

[15]Su SC, Maxwell SA, Bayless KJ.Annexin 2 regulates endothelialmorphogenesis by controlling AKT activation and junctionalintegrity[J].J Biol Chem, 2010, 285 (52) :40624-40634.

[16]Bao H, Jiang M, Zhu M, et al.Overexpression of Annexin IIaffects the proliferation, apoptosis, invasion and production ofproangiogenic factors in multiple myeloma[J].Int J Hematol, 2009, 90 (2) :177-185.

[17]Dai Z, Zhou J, Li XF, et al.An analysis of annexin II related to HCCmetastatic ability[J].Chin J Hepatol, 2007, 15 (8) :563-566.

[18]Yu GR, Kim SH, Park SH, et al.Identification of molecular markersfor the oncogenic differentiation of hepatocellular carcinoma[J].Exp Mol Med, 2007, 39 (5) :641-652.

[19]Longerich T, Haller MT, Mogler C, et al.Annexin A2 as a differentialdiagnostic marker of hepatocellular tumors[J].Pathol Res Pract, 2011, 207 (1) :8-14.

[20]Ji NY, Park MY, Kang YH, et al.Evaluation of annexin II as apotential serum marker for hepatocellular carcinoma using adeveloped sandwich ELISA method[J].Int J Mol Med, 2009, 24 (6) :765-771.

[21]Zhao P, Zhang W, Tang J, et al.Annexin II promotes invasion andmigration of human hepatocellular carcinoma cells in vitro via itsinteraction with HAb18G/CD147[J].Cancer Sci, 2010, 101 (2) :387-395.

[22]Zhang F, Zhang L, Zhang B, et al.Anxa2 plays a critical role inenhanced invasiveness of the multidrug resistant human breastcancer cells[J].J Proteome Res, 2009, 8 (11) :5041-5047.

[23] Kwaan HC, McMahon B.The role of plasminogen-plasmin systemin cancer[J].Cancer Treat Res, 2009, 148:43-66.

[24]O'Connell PA, Surette AP, Liwski RS, et al.S100A10 regulatesplasminogen-dependent macrophage invasion[J].Blood, 2010, 116 (7) :1136-1146.

[25]Marrero JA, Kudo M, Bronowicki JP.The challenge of prognosisand staging for hepatocellular carcinoma[J].Oncologist, 2010, 15 (Suppl 4) :23-33.

[26]Dong ZZ, Yao DF, Wu W, et al.Delayed hepatocarcinogenesisthrough antiangiogenic intervention in the nuclear factor-kappa Bactivation pathway in rats[J].Hepatobiliary Pancreat Dis Int, 2010, 9 (2) :169-174.

[27]Qian J, Yao D, Dong Z, et al.Characteristics of hepatic igf-ii expression and monitored levels of circulating igf-ii mRNA inmetastasis of hepatocellular carcinoma[J].Am J Clin Pathol, 2010, 134 (5) :799-806.

[28]Hofmann A, Osman A, Leow CY, et al.Parasite annexins--newmolecules with potential for drug and vaccine development[J].Bioessays, 2010, 32 (11) :967-976.

施引文献

资源附件(0)

访问统计